{"id":9987,"date":"2023-04-25T16:29:00","date_gmt":"2023-04-25T14:29:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=9987"},"modified":"2024-04-02T16:32:50","modified_gmt":"2024-04-02T14:32:50","slug":"difficult-to-treat-psoriatic-arthritis-how-should-we-manage","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/","title":{"rendered":"Difficult to treat psoriatic arthritis &#8211; how should we manage?"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">Anand Kumthekar 1, Maedeh Ashrafi 2, Atul Deodhar Clin Rheumatol. 2023 Sep;42(9):2251-2265. doi=10.1007\/s10067-023-06605-9. <\/p>\n<p>Psoriatic arthritis (PsA) is a chronic, multi-domain immune\u2013mediated inflammatory arthritis with a high disease burden. PsA patients have significant co-morbidities like obesity, depression, fibromyalgia which can impact disease activity assessment. The management of PsA has undergone a paradigm shift over the last decade due to the availability of multiple biologic and targeted synthetic disease modifying anti-rheumatic drugs. Despite the availability of multiple therapeutic agents, it is not uncommon to find patients not responding adequately and continuing to have active disease and\/or high disease burden. In our review, we propose what is \u201cdifficult to treat PsA\u201d, discuss differential diagnosis, commonly overlooked factors, co-morbidities that affect treatment responses, and suggest a stepwise algorithm to manage these patients.<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anand Kumthekar 1, Maedeh Ashrafi 2, Atul Deodhar Clin Rheumatol. 2023 Sep;42(9):2251-2265. doi=10.1007\/s10067-023-06605-9. Psoriatic arthritis (PsA) is a chronic, multi-domain immune\u2013mediated inflammatory arthritis with a high disease burden. PsA patients have significant co-morbidities like obesity, depression, fibromyalgia which can impact disease activity assessment. The management of PsA has undergone a paradigm shift over the last [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[815,699,424,80,53],"class_list":["post-9987","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-algorithm","scientific_tags-comorbidities","scientific_tags-gma","scientific_tags-psoriatic-arthritis","scientific_tags-refractory-patients"],"acf":{"sc_authors":"<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37097525\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/37097525\/<\/a>\r\n\r\n<a href=\"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06605-9\">https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06605-9<\/a>\r\n\r\n&nbsp;"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Difficult to treat psoriatic arthritis - how should we manage? - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Difficult to treat psoriatic arthritis - how should we manage? - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Anand Kumthekar 1, Maedeh Ashrafi 2, Atul Deodhar Clin Rheumatol. 2023 Sep;42(9):2251-2265. doi=10.1007\/s10067-023-06605-9. Psoriatic arthritis (PsA) is a chronic, multi-domain immune\u2013mediated inflammatory arthritis with a high disease burden. PsA patients have significant co-morbidities like obesity, depression, fibromyalgia which can impact disease activity assessment. The management of PsA has undergone a paradigm shift over the last [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-02T14:32:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/\",\"name\":\"Difficult to treat psoriatic arthritis - how should we manage? - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-04-25T14:29:00+00:00\",\"dateModified\":\"2024-04-02T14:32:50+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Difficult to treat psoriatic arthritis - how should we manage? - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/","og_locale":"fr_FR","og_type":"article","og_title":"Difficult to treat psoriatic arthritis - how should we manage? - Adacyte","og_description":"Anand Kumthekar 1, Maedeh Ashrafi 2, Atul Deodhar Clin Rheumatol. 2023 Sep;42(9):2251-2265. doi=10.1007\/s10067-023-06605-9. Psoriatic arthritis (PsA) is a chronic, multi-domain immune\u2013mediated inflammatory arthritis with a high disease burden. PsA patients have significant co-morbidities like obesity, depression, fibromyalgia which can impact disease activity assessment. The management of PsA has undergone a paradigm shift over the last [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/","og_site_name":"Adacyte","article_modified_time":"2024-04-02T14:32:50+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/","name":"Difficult to treat psoriatic arthritis - how should we manage? - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-04-25T14:29:00+00:00","dateModified":"2024-04-02T14:32:50+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/difficult-to-treat-psoriatic-arthritis-how-should-we-manage\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/9987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=9987"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=9987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}